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Background: β-catenin is the key protein in the WNT signalling pathway and it forms adherent junctions together
with E-cadherin. In ovarian carcinoma, abnormal expression of β-catenin, E-cadherin and WNT-1 was observed, but
their prognostic and predictive role is unclear. The aim of this study was to clarify the prognostic and predictive role
of E-cadherin, β-catenin and WNT-1 in advanced epithelial ovarian carcinoma (AEOC).
Methods: The expression of E-cadherin, β-catenin and WNT-1 was determined by immunohistochemistry in AEOC.
The correlation between expression of these proteins and progression-free survival (PFS) and overall survival (OS)
was evaluated. Statistical analyses included Kaplan-Meier estimation, log-rank test, Spearman correlation and Cox
proportional-hazards model.
Results: In ovarian cancer, intense expression of E-cadherin, β-catenin and WNT-1 was found. In multivariate
analysis, strong membrane β-catenin expression was an independent unfavourable predictor for PFS (HR 2.19,
95% CI 1.09-4.39; p = 0.028), while in univariate analysis, strong membrane β-catenin expression was a prognostic
factor for OS in patients with AOC (p = 0.039). In multivariate analysis, only resistance to first-line chemotherapy was
an adverse independent prognostic factor for OS (HR 16.84; 95% CI 5.07-55.98; p < 0.0001). Additionally, strong
membranous β-catenin expression was associated with resistance to platinum-based chemotherapy (p = 0.027).
Conclusions: These findings support that WNT/β-catenin pathway and E-cadherin are important factors in
advanced epithelial ovarian cancer.
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Epithelial ovarian cancer (EOC) is the most common ovar-
ian malignancy and accounts for 90% of cases of ovarian tu-
mours [1]. In 2008, it is estimated that worldwide there
were 224,747 women diagnosed with ovarian cancer and
140,163 deaths caused by ovarian cancer [2]. Ovarian car-
cinoma is the eighth most common cancer and the seventh
most frequent cause of cancer death in women [2]. 63% of
EOC patients have widespread disease at presentation [3].
Despite surgery and platinum-based systemic treatment the* Correspondence: lubo@esculap.pl
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stated.5-year survival for these patients is poor and accounts for
27% [3]. Therefore, prognostic and predictive factors for
better management of EOC patients are required.
The most important prognostic factors for EOC in-
clude: age, performance status, histology type, International
Federation of Gynaecology and Obstetrics (FIGO) stage
and tumour grade [4,5]. However, biochemical and mo-
lecular markers are becoming important variables. The
most significant marker is the level of cancer antigen 125
(CA-125), which is elevated in approximately 80% of
advanced ovarian cancer cases [6]. Serum CA-125 level
and its half-life are known to be correlated with OS and
PFS [7-9]. Additionally, it is also a marker of response to
chemotherapy [7,9-11].Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited. The Creative Commons Public Domain Dedication
ain/zero/1.0/) applies to the data made available in this article, unless otherwise
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lecular markers of the WNT/β-catenin pathway, which
is widely studied in EOC [12-14]. The WNT/β-catenin
pathway is triggered by WNT ligands, while β-catenin
is the “heart” of the pathway and activates expression
of many important proteins responsible for cell cycle,
proliferation and survival e.g. cyclin D1, c-Myc. Moreover,
β-catenin, together with E-cadherin, forms adherent junc-
tions mediating cell adhesion [15]. In the absence of WNT
ligands, β-catenin binds E-cadherin and forms complexes
in the cell membrane. Free cytosolic β-catenin is recruited
to a degradation complex constituted by anaphase pro-
moting complex (APC) protein, Axin, glycogen synthase
kinase 3β (GSK3β) and casein kinase I (CKI). GSK3β and
CKI phosphorylate β-catenin, which is subsequently
ubiquitinated by ubiquitin ligase protein (βTrCP) and de-
graded in the proteasome. WNT-1 binds to the frizzled/
lipoprotein receptor-related protein 5/6 (FZD/LRP5/6)
receptors and triggers inactivation of the degradation
complex. Unphosphorylated β-catenin is then transported
to the nucleus, where it binds T-cell factor/lymphoid
enhancer factor (TCF/LEF) and activates gene expression
of proteins responsible for cell cycle, proliferation and sur-
vival [16].
Deregulation of WNT/β-catenin pathway or altered ex-
pression of E-cadherin was found in many cancers as well
as in EOC [17,18]. One of the possible mechanisms of
WNT/β-catenin pathway alteration involves mutations of
the β-catenin gene (CTNNB1), which are found in endo-
metrioid subtype of ovarian cancer [19-21]. Additionally,
aberrant expression of β-catenin, E-cadherin and WNT-1
was observed in ovarian carcinoma [22-27]. The prognos-
tic role of β-catenin and E-cadherin are disputed, while
their impact on response to chemotherapy has never been
evaluated in ovarian cancer patients.
The aim of this study was to determine the expression
of β-catenin, E-cadherin and WNT-1 in advanced epi-
thelial ovarian cancers and to assess the correlation of
expression of the studied proteins with patient survival
and response to platinum-based chemotherapy. We found
changes in the expression of the studied proteins in ovar-
ian cancer cells. Moreover, strong membrane β-catenin
expression was identified as an unfavourable predictor for
PFS and was associated with resistance to platinum-based
chemotherapy for EOC patients.
Methods
Patients
We analysed medical records of all consecutive EOC pa-
tients treated in the Department of Oncology at the Military
Institute of Medicine in Warsaw, Poland between March
2001 and December 2007. The inclusion criteria were as
follows: (1) histologically confirmed advanced epithe-
lial ovarian cancer in FIGO stage III-IV; (2) history ofdebulking surgery followed by first-line chemotherapy
regimen: paclitaxel (135 mg/m2) with cisplatin (75 mg/m2)
or paclitaxel (175 mg/m2) with carboplatin (AUC6),
administered every 3 weeks for 6 cycles; (3) accessibility of
primary tumour specimens and full medical data. Response
to first-line chemotherapy according to RECIST criteria
(version 1.0), PFS and OS were obtained from medical re-
cords and analysed retrospectively. This study was ap-
proved by the institutional review board of the Military
Institute of Medicine in Warsaw (46/WIM/2009).
Immunohistochemistry
Immunohistochemical staining was performed on formalin-
fixed, paraffin-embedded primary tumours. Tissues were
sectioned at 3 μm and were mounted on Super Frost Ultra
Plus® slides (Menzel GmbH&co KG) and subjected to
antigen retrieval in Target Retrieval Solution, pH 9 (DAKO)
with PT Link (DAKO). Tissues were incubated with mouse
monoclonal anti-β-catenin antibody (dilution 1:100, clone
β-Catenin-1, DAKO), mouse monoclonal anti-E-cadherin
antibody (dilution 1:100, clone NCH-38, DAKO) or rabbit
polyclonal anti-WNT-1 antibody (dilution 1:100, Spring
Bioscience). Negative controls were incubated with mouse
or rabbit IgGs (DAKO). Subsequently, sections were incu-
bated with peroxidase-based EnVision™ + system (DAKO).
Colorectal epithelium was used as an external positive
control showing strong membranous expression of E-
cadherin and β-catenin.
Evaluation of the staining
The expression was scored by three independent ob-
servers (AS, SC, WK) without knowledge of the clinical
data. All membranous, cytoplasmic and nuclear staining
was evaluated in cancer cells. The intensity of mem-
brane staining was categorized as follows: strongly posi-
tive when intensity was equal to the intensity of cell
membrane in positive control and weakly positive corre-
sponding to the intensities between strong and negative.
The presence of cytoplasmic and nuclear staining was
graded into two groups: negative and positive if 10% of
tumour cells showed immunoreactivity.
Statistical analysis
Statistical analyses included descriptive statistics with de-
termination of minimal and maximal values, means and
medians, with 95% confidence interval (CI) for particular
variables. OS was defined as time elapsed between the date
of diagnosis and date of death or the date of last follow-up.
PFS was defined as the time from diagnosis until disease
recurrence or death or date of last follow-up. A Spearman
test for non-parametric variables was used to assess correl-
ation between histoclinical data and the expression of stud-
ied proteins. A Mann–Whitney U test for non-parametric
variables was used to assess if the expression of studied
Figure 1 Expression of E-cadherin, β-catenin and WNT-1 in ovarian ca
immunoreactivity in cancer cells Strong membranous, moderate cytoplasm
tissue. In ovarian carcinoma, there was strong WNT-1 immunoreactivity.
Table 1 Characteristics of patients (n = 46)
Characteristics n (%)
Age
Median 95% CI (years) 54 (52.1-57.4)

















G1 and G2 21 (45.6%)
G3 and unknown 25 (54.4%)
Primary surgery (with interval surgery)
Optimal debulking 27 (58.7%)
Suboptimal debulking 19 (41.3%)
Platinum sensitivity
Sensitive (>6 months) 31 (67.4%)
Resistant (<6 months) 15 (32.6%)
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therapy according to RECIST criteria (version 1.0). Univari-
ate analyses of variables influencing PFS or OS were
performed by log-rank test, which identified a preliminary
list of significant factors. All variables found to be signifi-
cant and factors that showed a trend towards significance
(p < 0.1) in the univariate analysis were included in the
multivariate analysis. Multivariate analyses of PFS and OS
were performed by Cox proportional-hazards regression
using the forward stepwise method. Median and life
tables were computed using the product-limit estimate by
the Kaplan and Meier method and the log-rank test was
employed to assess the statistical significance, p values less
than 0.05 were considered as significant. Statistical calcu-
lation was performed using the STATISTICA for Win-
dows Version 7.0 software.
Results
Among 132 patients with epithelial ovarian cancer in
our database, 46 were eligible. The main reasons for the
exclusion of patients from the study were lack of access
to tumour samples (71 patients) and early stage of EOC
(15 patients). Patient characteristics are summarized in
Table 1. Median age in the study group was 54 years (95%
CI; 52.1-57.4). The majority (69.6%) of patients were in
stage III of the disease. More than half of the patients had
the serous type of ovarian cancer and poorly differentiated
tumours (52.2% and 54.4%, respectively). Twenty-seven
(58.7%) patients underwent optimal debulking surgery (to-
gether with optional interval debulking surgery) and 67.4%
of the group was sensitive to first-line chemotherapy.
In ovarian cancer cells, membrane E-cadherin expres-
sion was strongly positive in 39 (84.8%) patients. More-
over the presence of cytoplasmic E-cadherin was observed
in tumours of almost all patients (45/46; 97.8%). Expres-
sion of β-catenin was strong in almost half of all pa-
tients (21/46; 45.6%). Moreover, β-catenin was presentncer. E-cadherin displayed strong membranous and cytoplasmic
ic and lack of nuclear expression of β-catenin was observed in tumour
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while it was absent in the cell nuclei in all EOC tumours.
In ovarian tumour cells, WNT-1 expression was present
in 31 (67.4%) women (Figure 1, Table 1).
To evaluate the impact of analysed proteins and histo-
clinical variables on EOC patients’ outcome, univariate
analysis was performed. The analysis revealed the identifi-
cation of several prognostic factors for PFS such as histo-
pathologic cell type and membranous β-catenin expression.Table 2 Univariate and multivariate analysis of progression-fr
Clinical parameter
Univariate analy
n (% ) Median (mon
Age
< 65 38 (82, 6%) 14, 1
≥ 65 8 (17, 4%) 23, 2
Histopathologic cell type
Serous 24 (52, 2%) 13, 8
Others 22 (47, 8%) 23, 2
Residual tumor size
<1 cm 19 (41, 3%) 21, 8
> 1 cm 27 (58, 7%) 10, 7
Performance status (ECOG)
0-1 43 (93, 5%) 16, 7
2 3 (6, 5%) 22, 0
Tumor grade
G1, G2 21 (45, 6%) 12, 9
G3, unknown 25 (54, 4%) 17, 5
E-cadherin membranous
Negative 7 (15, 2%) 16, 7
Positive 39 (84, 8%) 15, 9
E-cadherin cytoplasmic
Negative 1 (2, 2%)
Positive 45 (97, 8%) -
β-catenin membranous
Normal 21 (45, 6%) 9, 9
Decreased 25 (54, 4%) 22, 8
β-catenin cytoplasmic
Negative 27 (58, 7%) 15, 4
Positive 19 (41, 3%) 16, 7
β-catenin nuclear
Negative 46 (100, 0%) -
Positive 0 (0, 0%)
WNT-1
Normal 31 (67, 4%) 13, 5
Decreased 15 (32, 6%) 18, 8
NS - non significant.Age and residual tumour size revealed a prognostic trend
for PFS (Table 2). Serous type of tumour was associated
with shortened PFS (13.8 mo vs. 23.2 mo; p = 0.028).
Younger age and greater residual tumour size showed a
trend towards significance, while there was no association
between PFS and performance status or tumour grade.
Among analysed proteins, only membrane β-catenin was
a prognostic factor in univariate analysis. Patients with tu-
mours displaying strong expression of membranous β-ee survival
sis Multivariate analysis
ths) P value HR (95% CI) P value
0, 076 NS NS
0, 028 NS NS









Figure 2 Kaplan-Meier curves for PFS (A) and OS (B) by expression of membranous β-catenin. Red line: strong expression of β-catenin.
Blue line: weak expression of β-catenin.
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level of the studied protein (9.9 mo vs. 22.8 mo; p = 0.024)
(Figure 2). The expression of E-cadherin or WNT-1 were
not associated with PFS. In the multivariate analysis, only
intense expression of membrane β-catenin was an inde-
pendent adverse prognostic factor for PFS (HR 2.19, 95%
CI 1.09-4.39; p = 0.028).
In our study, we also found prognostic factors for OS
(Table 3). Patients resistant to first-line chemotherapy
had shortened OS in comparison to platinum-sensitive
tumours (21.7 mo vs. 93.4 mo; p < 0.001). Additionally,
serous ovarian carcinoma was associated with shortened
OS in comparison to other subtypes (62.5 mo vs. 80.8 mo;
p = 0.043). Among analysed proteins, only strong expres-
sion of membrane β-catenin was a prognostic factor for
shortened OS in univariate analysis (22.2 mo vs. 62.2 mo;
p = 0.039; Figure 2). Residual tumour size showed a trend
towards significance, while there was no association be-
tween OS and age, performance status or tumour
grade. In the multivariate analysis, only resistance to first-
line chemotherapy was an unfavourable prognostic factor
(HR 16.84; 95% CI 5.07-55.98; p < 0.0001).
We analysed the association between the intense ex-
pression of membrane β-catenin and the response to chemo-
therapy in the 29 patients with measurable disease according
to RECIST criteria (version 1.0). There was a difference
observed in complete response (CR), partial response
(PR), stable disease (SD) and progressive disease (PD) dis-
tribution according to membrane β-catenin expression
(p = 0.044). Eight (61.5%) EOC patients with tumours
demonstrating strong β-catenin expression in the cell mem-
brane had SD or PD, while most of the patients (14/16;
87.5%) with tumours displaying weak membrane β-catenin
expression had an objective response (CR + PR) that was
statistically significant (p = 0.027; Table 4).Discussion
In the present study, we analysed the expression of E-
cadherin, β-catenin and WNT-1 in advanced ovarian
carcinoma. We demonstrated the presence of E-cadherin
expression both in the cell membrane and cytoplasm of
ovarian tumour cells. The expression of E-cadherin has
been investigated in ovarian carcinoma, but in most of
the studies, patients in different stages of the disease
were examined [24,28]. According to the published data,
in the majority of cases of ovarian cancer, E-cadherin is up-
regulated unlike other type of cancers, where E-cadherin
expression is decreased [18]. Ovarian surface epithe-
lium displays epithelial and mesenchymal characteris-
tics and does not contain E-cadherin, but rather expresses
N-cadherin [22,29-32].
In primary and well-differentiated cancers E-cadherin
expression is high, while in advanced EOC, E-cadherin ex-
pression is moderate, although complete loss of E-cadherin
is rare [22,23,25,28-30,33]. Moreover, E-cadherin was
found in small cohesive tumour nodules floating in the
peritoneal cavity, in metastatic lesions and effusion speci-
mens [34-36]. We suggest that in metastatic cancer cells,
E-cadherin expression is required for cell survival. There
are several studies documenting that E-cadherin contrib-
utes to activation of the PI3K/AKT signalling pathway,
which controls cellular survival and proliferation [37-39].
In ovarian cancer cell lines, E-cadherin allows the re-
cruitment of PI3K-p85 regulatory subunit to the cell
membrane, leading to the activation of the p110 catalytic
subunit following signal transduction [39]. Additionally,
E-cadherin could also activate the MAPK pathway through
RAF [38]. These data indicate that E-cadherin may be im-
portant for ovarian cancer cell survival.
Furthermore, we detected intense expression of mem-
brane β-catenin in advanced EOC. Our results are
Table 3 Univariate and multivariate analysis of overall survival
Clinical parameter Univariate analysis Multivariate analysis
n (% ) Median (months)# P value HR (95% CI) P value
Age 0, 248
< 65 38 (82, 6%) 70, 1%
≥ 65 8 (17, 4%) 75, 0%
Histopathologic cell type 0, 043* NS NS
Serous 24 (52, 2%) 62, 5%
Others 22 (47, 8%) 80, 8%
Residual tumor size 0, 134
<1 cm 19 (41, 3%) 81, 1%
> 1 cm 27 (58, 7%) 55, 9%
Performance status (ECOG) 0, 276
0-1 43 (93, 5%) 71, 2%
2 3 (6, 5%) 66, 6%
Tumor grade 0, 498
G1, G2 21 (45, 6%) 32, 6
G3, unknown 25 (54, 4%) 40, 4
Sensitivity to first-line chemotherapy <0, 0001* 16, 84 (5, 07-55, 98) <0, 0001*
Resistant (<6 months) 26 (35, 1%) 21, 7%
Sensitive (>6 months) 48 (64, 9%) 93, 4%
E-cadherin membranous 0, 472
Negative 7 (15, 2%) 50, 0
Positive 39 (84, 8%) 35, 7
E-cadherin cytoplasmic 1 (2, 2%) - -
Negative 45 (97, 8%)
Positive
β-catenin membranous 0, 039* NS NS
Normal 21 (45, 6%) 22, 2
Decreased 25 (54, 4%) 62, 2
β-catenin cytoplasmic 0, 916
Negative 27 (58, 7%) 32, 6
Positive 19 (41, 3%) 40, 1
β-catenin nuclear - -
Negative 46 (100, 0%)
Positive 0 (0, 0%)
WNT-1 0, 846
Normal 31 (67, 4%) 33, 7
Decreased 15 (32, 6%) 40, 5
#If median was not achieved, the results were described as a percentage of patients with 2-year OS; NS- non significant; *The value of the probability of a
statistically significant (p <0.05); CI-confidence interval; HR- hazard ratio; ECOG- The Eastern Cooperative Oncology Group scale of performance status.
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catenin expression in ovarian tumours, but they differ
from the results reported by other groups where the ex-
pression of β-catenin was decreased [23,25]. Additionally,
Davidson et al. found that although there was no difference
in the intensity of β-catenin expression, there was areduction in the number of cells expressing membranous
β-catenin [33]. These results suggest that expression of β-
catenin is maintained in advanced ovarian carcinomas, but
at a moderate level. In vitro studies showed that shRNA-
mediated silencing of β-catenin resulted in inhibition of
proliferation and decreased capability of colony formation
Table 4 Association between membrane β-catenin expression and response to chemotherapy in patients according to
RECIST criteria (version 1.0)
Response to to chemotherapy
according to to RECIST
Normal membrane β-catenin expression Decreased membrane β-catenin expression Mann–Whitney
U test(n=13) (n=16)
n % n % P value
OR (CR+PR) 5 38.5 14 87.5 0.027*
SD+PD 8 61.5 2 12.5
CR 5 38.5 13 81.25 0.044*
PR 0 0.0 1 6.25
SD 6 46.1 1 6.25
PD 2 15.4 1 6.25
Abbreviations: *The value of the probability of a statistically significant (p <0.05); RECIST - Response Evaluation Criteria In Solid Tumours; CR - Complete Response;
PR - Partial Response; SD - Stable Disease; PD - Progressive Disease.
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studies, one can speculate that β-catenin is required for
proliferation of ovarian cancer cells. A similar effect was
observed in colorectal cancer, lung cancer and glioblast-
oma cells [41-43]. It means that the presence of β-catenin
might be required for proliferation and migration, but the
precise mechanism is still unknown and should be
determined.
β-catenin is also a key component of the signalling
pathway that is activated by WNT ligands. We showed
that in most of the ovarian tumours, there was a strong
WNT-1 expression; however, no nuclear β-catenin was
found. It might suggest that the WNT/β-catenin signal-
ling pathway was not activated despite the presence of
WNT-1 ligand. WNT-1 expression has been detected in
ovarian carcinomas [26,44]; however, other WNT li-
gands were also found such as WNT-5a, which was highly
expressed in EOC tumours [26,45]. Yoshioka et al. studied
expression of all WNT ligands at the mRNA level in
ovarian tumours. They found that WNT-3 and WNT-4
expression was reduced, while expression of WNT-7a and
WNT-7b was increased [46]. Additionally WNT-7a in-
creased expression was confirmed at the protein level
[46]. In humans, the WNT protein family consists of 19 li-
gands that can play a different role in signal transduction.
For example, WNT-1 and WNT-2 activates the canonical
WNT pathway, where β-catenin is a key protein, whereas
WNT-5a, WNT-7a and WNT-7b activate non-canonical
pathways including the planar cell polarity pathway or
WNT/Ca2+ pathway [47-49]. In ovarian cancers, both
types of ligand were found, which implicates that canon-
ical and non-canonical WNT pathways could control
ovarian carcinogenesis. Thus, further analysis of all WNT
ligands on a larger group of EOC patients is needed.
In our study, we found prognostic factors for OS and
PFS of EOC patients and predictors for chemotherapy
response. We revealed that strong membrane β-catenin
expression was an independent adverse prognostic factor
for PFS, while only resistance to first-line chemotherapywas an unfavourable prognostic factor for OS of advanced
ovarian cancer patients. Davidson et al. also investigated
the influence of β-catenin expression on advanced EOC
patient survival, but they did not find any statistically sig-
nificant correlation [33]. However, low membrane expres-
sion of β-catenin was shown to be an adverse prognostic
factor for OS of patients in different stages of the disease
[27,28]. On the other hand, preserved expression of mem-
brane β-catenin was associated with 10-year disease-
related survival and favourable recurrence-free survival of
EOC patients in univariate analysis [25]. Discordance be-
tween these results and ours could be due to differences
between the pattern of gene expression in the advanced
ovarian cancer and tumours confined to the primary site.
Shirdar et al. investigated genetic differences between
stages I/II and III/IV of ovarian tumours [50,51]. They
found that in advanced ovarian cancers, there were more
chromosomal gains and gene amplifications compared to
early carcinomas. Additionally, it has been reported that
activation and overexpression of BTAK/Aurora-A, which
is essential for chromosome segregation and centrosome
function, was associated with early stage EOC, while acti-
vation of phosphorylated AKT or SRC was associated with
advanced-stage disease [52-54]. The variety of genetic fea-
tures in early and advanced ovarian cancers may result in
a complex array of prognostic factors.
Finally, we found that strong membranous β-catenin
expression was associated with the lack of response to
chemotherapy, which corroborates in vitro studies. Silen-
cing of β-catenin leads to the increased sensitivity of
A2780 ovarian cancer cells to cisplatin, paclitaxel and
vincristine [40]. Moreover, metastatic melanoma cells
with β-catenin knocked down are more sensitive to
cisplatin, temozolomide and doxorubicin [55]. In addition,
cisplatin-resistant laryngeal carcinoma cells have increased
expression of β-catenin in the cell membrane [56]. It sug-
gests that expression of β-catenin might be associated
with the response to chemotherapy. Due to β-catenin
being observed in the cell membrane, but not in the
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herent junctions could be important in drug response.
One of the known mechanisms of drug resistance is the
cell-adhesion-mediated drug resistance (CAM-DR). The
association between cell adhesion and resistance of tumour
cells to anticancer agents was observed for the first
time by Sutherland [57]. Further studies showed cor-
relation between the expression of cell adhesion mol-
ecules and drug resistance: collagen VI, collagen XIA1
and connexin 43 were upregulated in cisplatin-resistant
ovarian carcinoma cells [58,59], while high expression of
claudin-7 was associated with a poor response to platinum-
based chemotherapy in EOC patients [60]. Additionally,
25% of overexpressed proteins identified in the carboplatin-
and paclitaxel-resistant tissues are the components of
the extracellular matrix (i.e. γ-catenin, δ-catenin) [61].
A range of proteins involved in cellular adhesion, includ-
ing β-catenin, may become new predictors of response to
platinum-based chemotherapy in ovarian carcinoma, but
more evidence showing their usefulness is needed.
Conclusions
In conclusion, our study showed the presence of β-
catenin and E-cadherin expression in advanced ovarian
cancers. Our results imply that β-catenin and E-cadherin
expression may be required for ovarian carcinogenesis be-
cause these proteins are involved in signalling pathways
that control cell proliferation. Additionally, β-catenin
could be responsible for resistance to chemotherapy, be-
cause some cell adhesion proteins are associated with re-
sistance of tumour cells to chemotherapy. Moreover, we
speculate that canonical and non-canonical WNT path-
ways could control ovarian carcinogenesis, because β-
catenin is absent in cancer cell nuclei, despite a strong
WNT-1 expression. These findings support that WNT/β-
catenin pathway, as well E-cadherin, are important in ad-
vanced epithelial ovarian cancer.
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